Latest Insider Transactions at Cyma Bay Therapeutics, Inc. (CBAY)
This section provides a real-time view of insider transactions for Cyma Bay Therapeutics, Inc. (CBAY). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of CymaBay Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of CymaBay Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 09
2023
|
Sujal Shah Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
64,861
-27.46%
|
$908,054
$14.2 P/Share
|
|
Oct 09
2023
|
Sujal Shah Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
64,861
+21.55%
|
$324,305
$5.0 P/Share
|
|
Sep 29
2023
|
Kurt Von Emster |
SELL
Open market or private sale
|
Direct |
15,921
-15.03%
|
$238,815
$15.68 P/Share
|
|
Sep 29
2023
|
Kurt Von Emster |
BUY
Exercise of conversion of derivative security
|
Direct |
15,921
+13.07%
|
$79,605
$5.0 P/Share
|
|
Sep 18
2023
|
Charles Mc Wherter President of R&D |
SELL
Open market or private sale
|
Direct |
21,746
-59.18%
|
$347,936
$16.22 P/Share
|
|
Sep 18
2023
|
Charles Mc Wherter President of R&D |
BUY
Exercise of conversion of derivative security
|
Direct |
21,746
+37.18%
|
$108,730
$5.0 P/Share
|
|
Sep 15
2023
|
Daniel Menold Vice President, Finance |
SELL
Open market or private sale
|
Direct |
0
|
$0
$16.87 P/Share
|
|
Sep 15
2023
|
Daniel Menold Vice President, Finance |
BUY
Exercise of conversion of derivative security
|
Direct |
16,545
+50.0%
|
$16,545
$1.77 P/Share
|
|
Sep 15
2023
|
Paul T Quinlan General Counsel |
SELL
Open market or private sale
|
Direct |
53,000
-100.0%
|
$848,000
$16.87 P/Share
|
|
Sep 15
2023
|
Paul T Quinlan General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
53,000
+50.0%
|
$106,000
$2.94 P/Share
|
|
Aug 18
2023
|
Charles Mc Wherter President of R&D |
SELL
Open market or private sale
|
Direct |
21,746
-59.18%
|
$239,206
$11.47 P/Share
|
|
Aug 18
2023
|
Charles Mc Wherter President of R&D |
BUY
Exercise of conversion of derivative security
|
Direct |
21,746
+37.18%
|
$108,730
$5.0 P/Share
|
|
Aug 15
2023
|
Daniel Menold Vice President, Finance |
SELL
Open market or private sale
|
Direct |
0
|
$0
$12.03 P/Share
|
|
Aug 15
2023
|
Daniel Menold Vice President, Finance |
BUY
Exercise of conversion of derivative security
|
Direct |
15,500
+50.0%
|
$77,500
$5.53 P/Share
|
|
Aug 15
2023
|
Paul T Quinlan General Counsel |
SELL
Open market or private sale
|
Direct |
5,000
-100.0%
|
$55,000
$11.91 P/Share
|
|
Aug 15
2023
|
Paul T Quinlan General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+50.0%
|
$10,000
$2.94 P/Share
|
|
Aug 09
2023
|
Daniel Menold Vice President, Finance |
SELL
Open market or private sale
|
Direct |
20,945
-100.0%
|
$251,340
$12.35 P/Share
|
|
Aug 09
2023
|
Daniel Menold Vice President, Finance |
BUY
Exercise of conversion of derivative security
|
Direct |
20,945
+50.0%
|
$104,725
$5.0 P/Share
|
|
Jul 18
2023
|
Charles Mc Wherter President of R&D |
SELL
Open market or private sale
|
Direct |
21,749
-59.18%
|
$239,239
$11.43 P/Share
|
|
Jul 18
2023
|
Charles Mc Wherter President of R&D |
BUY
Exercise of conversion of derivative security
|
Direct |
21,749
+37.18%
|
$108,745
$5.0 P/Share
|
|
Jul 14
2023
|
Paul T Quinlan General Counsel |
SELL
Open market or private sale
|
Direct |
5,000
-100.0%
|
$55,000
$11.81 P/Share
|
|
Jul 14
2023
|
Paul T Quinlan General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+50.0%
|
$10,000
$2.94 P/Share
|
|
Jun 30
2023
|
Paul T Quinlan General Counsel |
SELL
Open market or private sale
|
Direct |
5,000
-100.0%
|
$50,000
$10.05 P/Share
|
|
Jun 30
2023
|
Paul T Quinlan General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+50.0%
|
$10,000
$2.94 P/Share
|
|
Jun 20
2023
|
Charles Mc Wherter President of R&D |
SELL
Open market or private sale
|
Direct |
21,749
-59.18%
|
$173,992
$8.16 P/Share
|
|
Jun 20
2023
|
Charles Mc Wherter President of R&D |
BUY
Exercise of conversion of derivative security
|
Direct |
21,749
+37.18%
|
$108,745
$5.0 P/Share
|
|
May 18
2023
|
Charles Mc Wherter President of R&D |
SELL
Open market or private sale
|
Direct |
21,749
-59.18%
|
$195,741
$9.08 P/Share
|
|
May 18
2023
|
Charles Mc Wherter President of R&D |
BUY
Exercise of conversion of derivative security
|
Direct |
21,749
+37.18%
|
$108,745
$5.0 P/Share
|
|
May 15
2023
|
Paul T Quinlan General Counsel |
SELL
Open market or private sale
|
Direct |
5,000
-100.0%
|
$50,000
$10.37 P/Share
|
|
May 15
2023
|
Paul T Quinlan General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+50.0%
|
$10,000
$2.94 P/Share
|
|
Apr 17
2023
|
Dennis D Kim Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
112,219
-84.87%
|
$1,009,971
$9.54 P/Share
|
|
Apr 17
2023
|
Dennis D Kim Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
112,219
+45.91%
|
$448,876
$4.37 P/Share
|
|
Apr 13
2023
|
Dennis D Kim Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
7,781
-28.01%
|
$62,248
$8.98 P/Share
|
|
Apr 13
2023
|
Dennis D Kim Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,781
+21.88%
|
$31,124
$4.37 P/Share
|
|
Mar 28
2023
|
Dennis D Kim Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
100
-0.5%
|
$800
$8.98 P/Share
|
|
Mar 28
2023
|
Dennis D Kim Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
100
+0.5%
|
$400
$4.37 P/Share
|
|
Jun 06
2022
|
Sujal Shah Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
51,301
+23.05%
|
$51,301
$1.95 P/Share
|
|
Jan 19
2022
|
Dennis D Kim Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
20,000
+50.0%
|
$60,000
$3.04 P/Share
|